Core Viewpoint - The U.S. District Court has denied the FTC's request for a preliminary injunction to block the proposed acquisition of Surmodics by GTCR, marking a significant step towards the completion of the merger [1][3]. Group 1: Merger Details - The consummation of the merger is still subject to a Temporary Restraining Order, which prevents the parties from finalizing the merger before 5:00 p.m. Central time on November 17 [2]. - The merger agreement includes conditions such as the absence of any legal restraints, no material adverse effect on the company, and other customary closing conditions [2]. Group 2: Company Background - Surmodics is a leading provider of medical device and in vitro diagnostic technologies, focusing on performance coating technologies for intravascular medical devices and components for diagnostic tests [4]. - The company's mission is to improve disease detection and treatment, leveraging its expertise in surface modification and drug-delivery coating technologies [4].

Core Insights - Surmodics, Inc. presented results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia at the 23rd Annual VIVA Conference in Las Vegas [1] Company Summary - Surmodics, Inc. is a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry [1] Industry Context - The presentation was part of an industry-sponsored session, indicating active engagement and collaboration within the medical device sector [1]

Core Insights - Surmodics, Inc. announced a presentation discussing updated safety and performance data from the PROWL registry involving 160 patients with symptomatic lower extremity vessels treated with the Pounce™ Thrombectomy Platform [1] Company Overview - Surmodics, Inc. is a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry [1]